Correspondence 0001493152-24-029947 from Tevogen Inc. (TVGN)

Tevogen Inc.
Date: Aug. 1, 2024 · CIK: 0001860871 · Accession: 0001493152-24-029947

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-280414

Date

June 21, 2024

Author

Tevogen

Form

CORRESP

Company

Tevogen Inc.

Letter

Tevogen Bio Holdings Inc.

Independence Boulevard, Suite #410

Warren, New Jersey 07059

August 1, 2024

VIA EDGAR

United States Securities and Exchange Commission

F Street, NE

Washington, D.C. 20549

Re:

Tevogen Bio Holdings Inc.

Registration Statement on Form S-1

Filed June 21, 2024

File No. 333-280414

Request for Acceleration of Effectiveness

To the addressee above:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Tevogen Bio Holdings Inc. hereby requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) and declare the Registration Statement effective as of 4:30 p.m., Eastern Time, on August 2, 2024, or as soon thereafter as possible.

Please feel free to direct any questions or comments concerning this request to Nick Hoover of Hogan Lovells US LLP at (410) 659-2790, and once the Registration Statement has been declared effective, please notify Mr. Hoover by calling him at the same phone number.

Sincerely,
Tevogen
Bio Holdings Inc.

Show Raw Text

CORRESP
1
filename1.htm

Tevogen
Bio Holdings Inc.

15
Independence Boulevard, Suite #410

Warren,
New Jersey 07059

August
1, 2024

VIA
EDGAR

United
States Securities and Exchange Commission

100
F Street, NE

Washington,
D.C. 20549

    Re:

    Tevogen
    Bio Holdings Inc.

    Registration
    Statement on Form S-1

    Filed
    June 21, 2024

    File
    No. 333-280414

    Request
    for Acceleration of Effectiveness

To
the addressee above:

Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Tevogen Bio Holdings Inc. hereby requests
that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement on Form S-1 (the
“Registration Statement”) and declare the Registration Statement effective as of 4:30 p.m., Eastern Time, on August 2, 2024,
or as soon thereafter as possible.

Please
feel free to direct any questions or comments concerning this request to Nick Hoover of Hogan Lovells US LLP at (410) 659-2790, and once
the Registration Statement has been declared effective, please notify Mr. Hoover by calling him at the same phone number.

    Sincerely,

    Tevogen
    Bio Holdings Inc.

    /s/
    Ryan Saadi

    By:

    Ryan
    Saadi

    Title:

    Chief
    Executive Officer and Chairperson of the Board of Directors

SecProbe.io